William Blair Has Pessimistic Outlook of TRDA Q3 Earnings

Key Points

• William Blair has downgraded its earnings estimates for Entrada Therapeutics (TRDA), projecting Q3 2025 earnings per share (EPS) at ($0.88), down from a previous estimate of ($0.76).
• In its latest quarterly earnings, Entrada Therapeutics reported an EPS of ($1.04), missing the analysts' consensus estimate of ($0.86) by ($0.18).
• Several analysts have revised their ratings, with one firm lowering the stock from a "hold" to a "sell," while the overall consensus remains a "Moderate Buy" with an average price target of $25.67.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Research analysts at William Blair reduced their Q3 2025 earnings estimates for Entrada Therapeutics in a report issued on Wednesday, August 6th. William Blair analyst M. Minter now expects that the company will post earnings of ($0.88) per share for the quarter, down from their previous forecast of ($0.76). The consensus estimate for Entrada Therapeutics' current full-year earnings is $1.12 per share. William Blair also issued estimates for Entrada Therapeutics' Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.13) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.88) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($3.44) EPS and FY2027 earnings at ($3.83) EPS.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.18). Entrada Therapeutics had a negative net margin of 92.30% and a negative return on equity of 17.81%. The company had revenue of $1.98 million for the quarter, compared to analysts' expectations of $8.17 million.

A number of other equities analysts also recently commented on TRDA. Wall Street Zen downgraded shares of Entrada Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Entrada Therapeutics in a report on Tuesday, May 20th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $25.67.

Entrada Therapeutics Stock Down 3.4%

NASDAQ:TRDA traded down $0.18 during mid-day trading on Monday, reaching $5.14. The company's stock had a trading volume of 42,810 shares, compared to its average volume of 148,093. Entrada Therapeutics has a 1 year low of $4.93 and a 1 year high of $21.79. The stock has a fifty day moving average of $6.72 and a 200-day moving average of $8.86. The firm has a market capitalization of $195.51 million, a PE ratio of -2.89 and a beta of -0.12.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in TRDA. KLP Kapitalforvaltning AS acquired a new position in Entrada Therapeutics in the 4th quarter valued at $36,000. BNP Paribas Financial Markets acquired a new stake in shares of Entrada Therapeutics in the 4th quarter worth $57,000. Virtus ETF Advisers LLC acquired a new stake in shares of Entrada Therapeutics in the 4th quarter worth $68,000. Virtus Investment Advisers LLC increased its stake in shares of Entrada Therapeutics by 32.1% in the 2nd quarter. Virtus Investment Advisers LLC now owns 11,979 shares of the company's stock worth $80,000 after acquiring an additional 2,914 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of Entrada Therapeutics by 53,455.6% in the 4th quarter. Russell Investments Group Ltd. now owns 4,820 shares of the company's stock worth $83,000 after acquiring an additional 4,811 shares during the last quarter. Hedge funds and other institutional investors own 86.39% of the company's stock.

Insider Buying and Selling

In other Entrada Therapeutics news, major shareholder Ventures V. L.P. 5Am sold 6,935 shares of the company's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $7.50, for a total value of $52,012.50. Following the sale, the insider owned 1,093,313 shares in the company, valued at approximately $8,199,847.50. This represents a 0.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Kush Parmar sold 27,000 shares of the company's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $7.50, for a total value of $202,500.00. Following the completion of the sale, the director owned 1,093,313 shares in the company, valued at approximately $8,199,847.50. This represents a 2.41% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 254,000 shares of company stock worth $1,782,000. 8.11% of the stock is owned by insiders.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.